Issue 4, 2023

Amenamevir by Ugi-4CR

Abstract

We report a concise, convenient and sustainable synthesis of the approved anti-herpes zoster drug, Amenamevir. Based on the Ugi-4CR, our approach can access Amenamevir by a simple, rapid and one-pot synthesis. Compared to other reported syntheses, ours is more sustainable, shorter, and higher yielding. The X-ray crystal structures of key intermediate 3-(4-isocyanophenyl)-1,2,4-oxadiazole 4 and Amenamevir are reported for the first time. Computational retrosynthesis of Amenamevir using four popular freeware could recapitulate the described multi-step approaches but disappointingly did not propose our one-pot synthesis.

Graphical abstract: Amenamevir by Ugi-4CR

Associated articles

Supplementary files

Article information

Article type
Communication
Submitted
23 Dec 2022
Accepted
30 Jan 2023
First published
01 Feb 2023
This article is Open Access
Creative Commons BY license

Green Chem., 2023,25, 1322-1325

Amenamevir by Ugi-4CR

X. Li, T. Zarganes-Tzitzikas, K. Kurpiewska and A. Dömling, Green Chem., 2023, 25, 1322 DOI: 10.1039/D2GC04869H

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements